Market Trends
Worldwide hepatitis C market expected to reach $3.97 billion by 2007
Published in Hepatitis Weekly, July 22nd, 2002
The worldwide market for hepatitis C therapeutics is expected to reach nearly $4 billion by 2007, driven both by a growing patient population and the emergence of promising new drugs. For example pegylated interferons, such as PEG-Intron by Schering-Plough and Pegasys by Hoffmann-La Roche, should impact the U.S. market over the next 2 years, according to a new Front Line Strategic Market Report entitled "Hepatitis C Therapeutics, Emerging Trends and Opportunities."
Hepatitis C affects nearly 4 million Americans and 170 million people worldwide, and is one of the most significant causes of chronic liver disease. The highly infectious virus enters the bloodstream...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2002-07-22)
More Articles from Hepatitis Weekly
- End-Stage Liver Disease
Advances no longer preclude transplantations for hepatitis B virus - Ultrasound
Doppler images distinguish acute alcoholic hepatitis from cirrhosis - Chemotherapy
Cancer agent Doxil improves outcomes after ablation of liver tumors - Poisoning
Livers from those with methanol intoxication acceptable for organ recipients - Tumor Markers
Protein offers new way to detect liver cancer in people with cirrhosis - Bioengineering
Coating polymers with growth factor improves liver cell transplantation - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
